Controlled Therapeutics receives grant from Scottish government
This article was originally published in Scrip
Controlled Therapeutics (Scotland) has received a £930,000 grant from the Scottish Executive's regional selective assistance programme, which will go towards creating 23 new positions at its East Kilbride facility. The company, a subsidiary of the US firm Cytokine PharmaSciences, conducts research and manufacturing there, and Cytokine Pharmasciences' president and CEO Dennis Wilson said the company was investing $6 million in Scotland. Patent protection on its Hydrogel technology, which was acquired from the University of Strathclyde, runs out in 2012, but it plans to develop both its existing polymer technology and new technologies based on linear polymers.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
European biotech Pharvaris has received series C funding to support its novel potential therapy for hereditary angioedema, in a competitive sector of drug development.
Top-line results from BrainStorm’s NurOwn Phase III ALS study show the cell therapy missed the primary efficacy endpoint, but clinically meaningful responses were seen in a pre-specified subgroup which investigators considered potentially a significant step forward in therapy.